Document:

EX-10.9

 Exhibit 10.9 
 BIND BIOSCIENCES, INC. 
 March 20, 2013 

Dr. Gregory Berk 
 332 South McCadden Place

 Los Angeles, California 90020 
  

	 	Re:	Employment Terms 

 Dear Greg: 

BIND Biosciences, Inc. (the “Company”), is pleased to offer you full-time employment as the Company’s Chief Medical
Officer. You will be responsible for such duties as are normally associated with such position or as otherwise determined by the Company. You will report to Scott Minick, the President and Chief Executive Officer of the Company, or such other
individual as the Company may designate (in any case, the “Supervisor”). Your primary place of employment will initially be in the Company’s offices located in Cambridge, Massachusetts; however, you will be excepted to travel
as may be necessary to fulfill your responsibilities. In the course of your employment with Company, you will be subject to and required to comply with all company policies and all applicable laws and regulations. 

You will be paid a base salary at the weekly rate of $6,730.77, subject to required tax withholding and other authorized deductions. Your
base salary will be payable in accordance with the Company’s standard payroll policies and subject to adjustment pursuant to the Company’s policies as in effect from time to time. The vesting and other terms of the agreements governing the
options to purchase shares of the Company’s common stock you have been granted during the course of your service as a consultant of the Company prior to the date of this letter will continue to apply during the period of your employment with
the Company. In addition, the Company will reimburse you for such reasonable moving expenses incurred in connection with the relocation of your primary residence to the Cambridge, Massachusetts area as you and the Company may mutually agree.

 You will be eligible to participate in all of the employee benefits and benefit plans that the Company generally makes
available to its regular full-time employees. In addition, during your employment, you will be eligible for other standard benefits to the extent applicable generally to other similarly situated employees of the Company. The Company reserves the
right to terminate, modify or add to its benefits and benefit plans at any time. 
 The Company requires that, as a full-time
employee, you devote your full business time, attention, skill and efforts to the tasks and duties of your position as assigned by the Company. If you wish to request consent to provide services (for any or no form of compensation) to any other
person or business entity while employed by the Company, please discuss that with your Supervisor in advance of accepting another position. 

 As a condition of employment, you will be required to (1) sign and comply with a
Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement, a copy of which is attached hereto as Exhibit A (the “NDA”), which, among other things, prohibits unauthorized use or disclosure of Company
proprietary information, (2) sign and return a satisfactory I-9 immigration form and provide sufficient documentation establishing your employment eligibility in the United States of America and (3) provide satisfactory proof of your
identity as required by United States law. By signing below, you represent that your performance of services to the Company will not violate any duty which you may have to any other person or entity (such as a present or former employer or a
governmental authority), including obligations concerning providing services (whether or not competitive) to others, confidentiality of proprietary information and assignment of inventions, ideas, patents or copyrights, and you agree that you will
not do anything in the performance of services hereunder that would violate any such duty. 
 Notwithstanding anything in this
letter to the contrary, your employment with the Company is “at will”. This means that it is not for any specified period of time and can be terminated by you or by the Company at any time, with or without advance notice, and for any or no
particular reason or cause. The Company does, however, request that that you provide at least two weeks’ written notice in the event you decide to resign other than for Good Reason (as defined below). The at-will nature of your employment also
means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as the Company’s personnel policies and procedures, may be changed with prospective effect, with or without notice, at
any time in the sole discretion of the Company, subject to the terms of this letter. 
 If the Company terminates your
employment without Cause (as defined below) or you resign your employment for Good Reason (in either event, a “Qualifying Termination”), subject to your execution of a release acceptable to the Company (the
“Release”) within the 30-day period following your Separation from Service (as defined below), the expiration of any revocation period provided in the Release and your continued compliance with the NDA, the Company will pay you an
amount equal to your then-current base salary rate for a period of four (4) months plus one month for each full year of continuous service to the Company up to the date of your termination of employment, not to exceed six (6) months in the
aggregate (the “Severance Amount”); provided that the Severance Amount will be equal to your then-current base salary rate for a period of six (6) months if the Qualifying Termination occurs within the three (3) months
immediately preceding or the twelve (12) months immediately following a Qualified Sale (as defined below). The Severance Amount will be paid in substantially equal installments in accordance with the Company’s ordinary payroll practices
over four (4) months plus one month for each full year of continuous service to the Company up to the date of your termination of employment, not to exceed six (6) months in the aggregate (the “Severance Period”),
beginning on the first payroll date following the date that is 40 days after the date of your Separation from Service; provided that the Severance Period will be six (6) months if the Qualifying Termination occurs within the three
(3) months immediately preceding or the twelve (12) months immediately following a Qualified Sale. In addition, if you timely elect continued group medical insurance coverage pursuant to COBRA, the Company will reimburse you for the
applicable premiums for you and your eligible dependents during the period commencing on the 

  
 2 

 
date of your Separation from Service and ending on the earliest to occur of (a) the final day of the Severance Period, (b) the date you and/or your eligible dependents are no longer
eligible for COBRA and (c) the date you become eligible to receive medical insurance coverage from a subsequent employer. Notwithstanding the foregoing, if the Company determines that it cannot provide such reimbursement of premiums to you
without potentially violating applicable law, the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to continue your group medical insurance
coverage in effect on the date of your termination of employment (based on the premium for the first month of COBRA coverage), which payment will be made regardless of whether you elect COBRA continuation coverage and will commence in the month
following the month in which your Separation from Service occurs and end on the earliest to occur of (x) the final day of the Severance Period, (y) the date you and/or your eligible dependents are no longer eligible for COBRA and
(z) the date you become eligible to receive medical insurance coverage from a subsequent employer. 
 For purposes of this
letter, the Company will have “Cause” to terminate your employment or service upon (i) your failure to substantially perform your duties with the Company or comply with, in any material respect, any of the Company’s
policies to which you are subject; (ii) a determination by the Company that you failed in any material respect to carry out or comply with any lawful and reasonable directive of the Company; (iii) your breach of a material provision of any
agreement between you and the Company; (iv) your conviction, or plea of no contest or nolo contendere, or the imposition of unadjudicated probation on you for any felony or crime involving moral turpitude; (v) your unlawful use
(including being under the influence) or possession of illegal drugs on the Company’s (or any of its affiliates’) premises or while performing your duties and responsibilities for the Company (or any of its affiliates); or (vi) your
commission of an act of fraud, embezzlement, misappropriation, willful misconduct or breach of fiduciary duty against the Company or any of its affiliates. 
 For the sole purpose of determining your right to separation payments and benefits hereunder, your resignation will be for “Good Reason” if you resign your employment immediately
following any of the following: (A) a change in your principal work location despite your stated disagreement with such a change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for
Company business shall not be deemed a change in principal work location); (B) a material reduction by the Company without your consent in your base salary or benefits (provided, that if the Company’s Board of Directors has determined that
it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not constitute Good Reason if (1) the reduction of the salary and benefits is proportionate to the reduction imposed on other
executives of the Company of similar seniority and (2) the reduction does not reduce the salary and benefits by more than 20% below the level then in effect); or (C) a material reduction by the Company without your consent in your duties,
position, title, or responsibilities (unless such reduction occurs after a Qualified Sale in which case a mere change in title or reporting responsibilities will not constitute Good Reason). 

For the purposes of this letter, “Qualified Sale” shall mean the sale of all or substantially all of the assets or
issued and outstanding capital stock of the Company, or merger or consolidation involving the Company in which stockholders of the Company immediately before 

  
 3 

 
such merger or consolidation do not own immediately after such merger or consolidation capital stock or other equity interests of the surviving corporation or entity representing more than fifty
percent (50%) in voting power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger or consolidation. 

For purposes of this letter, “Separation from Service” means a “separation from service” within the meaning of
Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”). Each installment payment provided under this letter shall at all times be considered a separate and distinct payment for purposes of Section 409A
of the Code. Notwithstanding anything in this letter to the contrary, to the extent required to avoid a prohibited distribution under Section 409A of the Code, the benefits provided under this letter will not be provided to you until the
earlier of (a) the expiration of the six-month period measured from the date of your Separation from Service with the Company or (b) the date of your death. Upon the first business day after expiration of the relevant period, all payments
delayed pursuant to the preceding sentence will be paid in a lump sum and any remaining payments due under this letter will be paid as otherwise provided herein. 
 If you accept this offer, this letter and the NDA shall constitute the complete agreement between you and Company with respect to the terms and conditions of your employment, and the term of the
Consulting Agreement, dated as of May 15, 2012, between you and BIND (the “Consulting Agreement”) will continue until, and expire automatically upon, the date you commence employment with the company as a regular, full-time
employee. Any prior or contemporaneous representations (whether oral or written) pertaining to your employment with the Company not contained in this letter or the NDA, or contrary to those contained in this letter or the NDA, that may have been
made to you are expressly cancelled and superseded by this offer; provided that, for the avoidance of doubt, your obligations under the provisions of Section 5 (Developments) and Section 6 (Confidentiality) of the Consulting
Agreement shall survive. 
 This offer letter shall be interpreted and construed in accordance with the laws of the Commonwealth
of Massachusetts without regard to any conflicts of laws principles. While other terms and conditions of your employment may change in the future, the at-will nature of your employment may not be changed, except in a subsequent letter or written
agreement, signed by you and the Chief Executive Officer of the Company. 
 If you wish to accept employment at the Company
under the terms described above, please sign and date this letter and the NDA and return them to me by fax at (617) 491-0351 or by email at ScottMinick@bindbio.com not later than seven days following the date hereof, after which time this offer
of employment will expire. If you accept our offer, we would like you to commence your employment with us as soon as practicable. 
 If you have any questions, regarding this letter or employment with the Company, please feel free to contact me. We look forward to your favorable reply and to a productive and enjoyable work
relationship. 
 [Signature Page Follows] 

  
 4 

 
			
	Sincerely,
	
	BIND BIOSCIENCES, INC.
		
	By:	 	 /s/ Scott Minick

	Name:	 	Scott Minick
	Title:	 	President & Chief Executive Officer

  

	
	Accepted by:
	
	 /s/ Gregory Berk

	Gregory Berk
	
	 March 20, 2013

	Date:

  
 5 

 BIND BIOSCIENCES, INC. 
 March 13, 2013 
 Dr. Gregory Berk 

332 S. McCadden Place 
 Los Angeles, California
90020 
 Dear Greg: 
 The purpose of
this letter is to set forth an amendment to each of the following options (collectively, the “Options”) to purchase shares of Common Stock of BIND Biosciences, Inc. (the “Company”) that were granted to you under the
Company’s 2006 Stock Incentive Plan: 
  

									
	 Date of Grant
	  	Number of Shares	 	  	Exercise Price	 
			
	 June 12, 2012
	  	 	292,342	  	  	$	0.96	  
	 October 16, 2012
	  	 	20,000	  	  	$	0.96	  

 Each of the Options is hereby amended to provide for the acceleration in full of the vesting of all shares subject to
such Option upon the first to occur of the following, in each case, after the closing of a Qualified Sale (as defined below) and to the extent the unvested portion of such Option has not been forfeited prior to the applicable date, (a) the date
that is 360 days after the closing of such Qualified Sale, (b) the termination by the Company of your employment with the Company within 360 days after the closing of such Qualified Sale or (c) the termination by you of your employment
with the Company for Good Reason (as defined below) within 360 days after the closing of such Qualified Sale. For purposes hereof, (1) “Qualified Sale” shall mean the sale of all or substantially all of the assets or issued and
outstanding capital stock of the Company, or merger or consolidation involving the Company in which stockholders of the Company immediately before such merger or consolidation do not own immediately after such merger or consolidation capital stock
or other equity interests of the surviving corporation or entity representing more than fifty percent in voting power of capital stock or other equity interests of such surviving corporation or entity outstanding immediately after such merger or
consolidation and (2) “Good Reason” shall mean any termination of your employment by you immediately following any of the following: (a) a change in your principal work location despite your stated disagreement with such a
change, to a location more than 60 miles from the Company’s current location in Cambridge, Massachusetts (travel for Company business shall not be deemed a change in principal work location); (b) a reduction by the Company in your salary
or benefits (provided, that if the Company’s Board of Directors has determined that it is in the best interests of the Company to reduce compensation and benefits generally, such reduction shall not qualify as a termination for Good Reason if
(i) the reduction of the salary and benefits is proportionate to the reduction imposed on other executives of the Company of similar seniority and (ii) the reduction does not reduce the salary and benefits by more than 20% below the level
then in effect); or (c) a reduction by the Company in your duties, position, title, or responsibilities (unless such reduction occurs after a Qualified Sale in which case a mere change in title or reporting responsibilities shall not constitute
Good Reason). 
  

			
	Very truly yours,
	
	BIND BIOSCIENCES, INC.
		
	By:	 	 /s/ Andrew Hirsch

		 	Andrew Hirsch
		 	Chief Financial Officer
	
	AGREED:
	
	 /s/ Gregory Berk

	Gregory BerkEX-10.10

 Exhibit 10.10 
 AMENDED AND RESTATED EMPLOYMENT AGREEMENT 
 THIS AMENDED AND RESTATED
EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of June, 2013 is entered into by BIND Therapeutics, Inc. (f/k/a BIND Biosciences, Inc.), a Delaware corporation (the “Company”), and Daniel S. Lynch, an individual
residing at 7 Calhoun Drive, Greenwich, Connecticut 06831 (the “Executive”). 
 WHEREAS, the Company and the Executive
previously entered into that certain Employment Agreement, dated September 7, 2012 (the “Employment Agreement”); and 
 WHEREAS, the Company and the Executive desire to amend and restate the Employment Agreement in its entirety to read as set forth herein. 

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by the parties hereto, the parties agree that the Employment Agreement is hereby amended and restated in its entirety to read as follows: 

1. Services. The Executive agrees to be employed by the Company, performing such senior executive duties as may be reasonably
requested from time to time by the Board of Directors of the Company (the “Board”). The Executive agrees to devote twenty percent (20%) of his business time (which, on average, shall be one business day per week) to the performance of
such duties at such times and places as shall be mutually agreed to by the Board and the Executive. The Company agrees to cause the Executive to be elected to the Board as Chairman of the Board, and Executive agrees to serve in such capacity. The
Executive shall serve on the Board until such time as this Agreement shall terminate pursuant to Section 4.1 herein, at which time the Executive shall resign from the Board and from all positions as an officer or director of the Company.

 2. Term. This Agreement shall commence on the date hereof and shall continue until terminated in accordance with the
provisions of Section 4.1 (such period, the “Employment Period”). 
 3. Compensation. 

3.1 Salary/Bonus. The Company shall pay to the Executive a base salary of $16,667 per month ($200,000 on an annual basis), payable
in accordance with the Company’s normal payroll practices for its executives. Payment for any partial month shall be prorated. The Executive will be eligible to receive an annual performance bonus on the same terms, and subject to the same
conditions, as the Company’s Chief Executive Officer (“CEO”). 
 3.2 Equity. 

(a) Equity Grants. The Executive was previously granted nonstatutory stock options (the “Options”) under the
Company’s 2006 Stock Incentive Plan (the “Plan”) for the purchase of an aggregate of 1,178,431 shares of common stock of the Company (the “Shares”) as follows: 

(i) an Option to purchase 762,862 Shares granted on September 7, 2012, and an Option to purchase 33,375 Shares granted on
October 16, 2012 (collectively, “Option 1”). 

 (ii) an Option to purchase 183,087 Shares granted on September 7, 2012, and an Option
to purchase 8,010 Shares granted on October 16, 2012 (collectively “Option 2”), each of which vests, subject to the terms of the stock option award agreement (“Stock Option Agreement”) governing the Option, generally, upon
the Determination Date (as defined in the applicable Stock Option Agreement) which must occur on or before the Cutoff Date (as defined in the applicable Stock Option Agreement), if certain performance conditions are attained. 

(iii) an Option to purchase 183,087 Shares granted on September 7, 2012, and an Option to purchase 8,010 Shares granted on
October 16, 2012 (collectively, “Option 3”), each of which (as amended on the date hereof) vests, subject to the terms of the applicable Stock Option Agreement, generally, upon the date certain performance conditions are attained.

 (b) Acceleration Upon a Sale. With respect to Option 1 and Option 2, notwithstanding the vesting schedules set forth
in the applicable Stock Option Agreements, upon the closing of a Sale (as defined below) of the Company, the vesting schedule of such Options shall be accelerated in full and such Options shall be exercisable for the purchase of all or any portion
of the full number of Shares underlying such Options at such time. A “Sale” of the Company shall be any sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger,
consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Company’s voting securities immediately prior to such
transaction beneficially own, directly or indirectly, more than 50% (determined on an as-converted basis) immediately following the transaction of the outstanding securities entitled to vote generally in the election of directors of the resulting,
surviving or acquiring corporation in such transaction). 
 (c) Additional Option. On the date of this Agreement, the
Company will grant the Executive an Option (“Option 4”) under the Plan for the purchase of 355,731 shares of common stock of the Company at a purchase price of $3.57 per Share, which Option shall be evidenced by an agreement in
substantially the form attached hereto as Exhibit A. The shares underlying Option 4 are intended to represent a one percent (1.0%) ownership interest in the Company as of the date hereof (based on the number of shares of Fully Diluted Equity of
the Company as of the date hereof, after giving effect to the issuance of Option 4). “Fully Diluted Equity of the Company” means the common stock of the Company outstanding as of the determination date, assuming the exercise on such date
of all outstanding options, warrants and other rights to purchase common stock of the Company or securities convertible into common stock of the Company and the conversion on such date of all securities convertible into common stock of the Company.

 3.3 Expenses. The Company shall reimburse the Executive for all reasonable documented out of pocket expenses incurred
or paid by the Executive in connection with, or 

  
 - 2 -

 
related to, the performance of his duties under this Agreement, including Executive’s travel and lodging expenses. The Executive shall submit to the Company itemized monthly statements of
such expenses incurred in the previous month. The Company shall pay to the Executive amounts shown on each such statement within thirty (30) days after receipt thereof. The Company shall pay the reasonable and documented fees and expenses of
Wilmer Cutler Pickering Hale and Dorr LLP, counsel for the Executive, incurred in connection with the preparation and negotiation of this Agreement. 
 3.4 Benefits. The Executive and the members of his immediate family shall be entitled to participate in all health and dental benefit programs that the Company establishes and makes available to
its employees if the Executive is not at the time receiving such benefits from another employer. In addition, the Executive shall be entitled to participate in all other benefit programs that the Company establishes and makes available to its
employees, if any, to the extent that Executive’s position, tenure, salary, age, health and other qualifications make him eligible to participate. The Executive shall be entitled to paid vacation in accordance with the Company vacation policy,
to be taken at such times as may be approved by the Board or its designee. 
 3.5 Termination for Good Reason.

 (a) In the event that the Executive terminates this Agreement for Good Reason (as defined below), then provided that on or
after the effective date of such termination the Executive executes (and does not revoke) a general release of claims in the form attached hereto as Exhibit B (the “Release”) and the Release becomes effective and irrevocable
within forty-five (45) days following the effective date of such termination, (x) the Executive shall be entitled to the salary that would have been payable to the Executive pursuant to Section 3.1 during the Post Termination Period,
which amount shall be paid in substantially equal installments over the Post Termination Period in accordance with the ordinary payroll practices of the Company, provided that any payments that would otherwise be payable to the Executive prior to
the first regular payroll date to occur not less than forty-five (45) days following the effective date of termination of this Agreement (the “First Payment Date”) shall be accumulated and paid, if at all, on the First Payment Date,
(y) the portion of Option 1 that would have vested during the Post Termination Period if this Agreement was not so terminated shall immediately vest and (z) the Executive shall be entitled to vest on the Determination Date in any portion
of Option 2 that would have vested during the Post Termination Period if this Agreement was not so terminated. For purposes of this Agreement, “Post Termination Period” shall mean a period immediately following the effective date of the
termination of this Agreement of nine (9) successive months. 
 (b) For purposes of this Agreement, “Good
Reason” means: (i) any material diminution or other material adverse change in the Executive’s authority, title, or duties under this Agreement without the prior consent of the Executive or (ii) a material breach by the Company
of the terms of this Agreement; provided that in each case the Executive shall have delivered written notice to the Company of the occurrence of any of the foregoing within 90 days of the initial occurrence of such event, including a summary
thereof, the Company shall not have remediated such matter during the thirty (30) day period following its receipt of such notice, and the date of termination is within two years of the initial occurrence of such event. 

  
 - 3 -

 3.6 Withholding. All salary, bonus and other compensation payable to the Executive
shall be subject to applicable withholding taxes. 
 4. Termination. 

4.1 This Agreement may be terminated as follows: 
 (a) by the Executive other than for Good Reason, upon not less than nine (9) months’ prior written notice to the Company; 

(b) by the Executive for Good Reason, in accordance with the notice provisions provided under Section 3.5(b) but without any
additional notice period; 
 (c) by the Company for Cause, in accordance with the notice provisions provided under
Section 4.2 but without any additional notice period; and 
 (d) by the Company without Cause, upon nine months’
prior notice to the Executive. 
 In the event of any termination of this Agreement, the Executive (or, as applicable, his family) shall be
entitled, as to all periods prior to the effective date of termination, to payment in accordance with Section 3.1, benefits under Section 3.3 and reimbursement of expenses in accordance with Section 3.3. In the event of any
termination of this Agreement pursuant to clause (a) or (d) of this Section 4.1, (I) notwithstanding anything in this Agreement to the contrary, from the date of notice of such termination until the effective date of termination,
the Executive shall perform only such services as shall be mutually agreed to by the Executive and the Company, and the Executive may resign as a member of the Board with immediate effect if the Executive believes that his continued service on the
Board would be inappropriate under the circumstances, (II) provided, however, that (A) clause (I) of this sentence shall only apply if the Executive executes and delivers the Release to the Company on or after the date of the notice of
termination of the Agreement under clause (a) or (d) of this Section 4.1 is given (the “Trigger Date”), and the Release becomes irrevocable and effective within forty-five (45) days following the Trigger Date,
(B) following the Trigger Date, no payments shall be made to the Executive under clause (a) or (d) of this Section 4.1 prior to the first regular payroll date that is forty-five (45) days following the Trigger Date and any
payments that would otherwise be payable to the Executive prior to such date shall be accumulated and paid, if at all, on the first regular payroll date to occur not less than forty-five (45) days following the Trigger Date and (C) if the
Release does not become irrevocable and effective within forty-five (45) days following the Trigger Date, then the Executive shall cease to be entitled to any compensation or benefits under this Agreement or any other agreement with the Company
or its affiliates for periods after the Trigger Date, including without limitation any vesting or accelerated vesting of any equity-based awards; provided, however, Executive shall be able to exercise or retain any equity-based awards under the
terms of such awards as if Executive was terminated on the Trigger Date. 
 4.2 For purposes of this Agreement,
“Cause” means: (i) that (x) the Executive has willfully and intentionally failed to substantially perform his reasonably assigned duties for the Company or to follow the applicable material policies or procedures of the Company
in 

  
 - 4 -

 
effect from time to time and such non-performance continues for a period of ten (10) business days following written notice by the Company to the Executive of such failure, or (y) the
Executive has engaged in an act of material dishonesty, fraud or willful misconduct in connection with the Executive’s duties hereunder or in dealings with the Company or knowing engagement in conduct which reasonably would be expected to be
materially detrimental or injurious (monetarily or otherwise) to the Company; or (ii) the conviction of the Executive of, or the entry of a pleading of guilty or nolo contendere by the Executive to, any felony, other than automobile violations.

 5. Cooperation. The Company shall provide such access to its information and property as may be reasonably required in
order to permit the Executive to perform his obligations hereunder. The Executive shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and
security requirements of the Company concerning the safety of persons and property. 
 6. Proprietary Information and
Inventions. 
 6.1 Proprietary Information. 

(a) The Executive acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his
employment with the Company he will have access to and contact with Proprietary Information (as defined below). The Executive will not disclose any Proprietary Information to any person or entity other than employees of the Company or use the same
for any purposes (other than in the performance of his duties as an employee or director of the Company) without prior written approval from the CEO, either during or after the term of the Employment Agreement or during or after the Employment
Period, unless and until such Proprietary Information has become public knowledge without fault by the Executive. 
 (b) For
purposes of this Agreement, Proprietary Information shall mean, by way of illustration and not limitation, all information, whether or not in writing, whether or not patentable and whether or not copyrightable, of a private, secret or confidential
nature, owned, possessed or used by the Company, concerning the Company’s business, business relationships or financial affairs, including, without limitation, any Invention (as defined below), formula, vendor information, customer information,
patient information, collaborator information, apparatus, equipment, trade secret, process, research, report, technical or research data, clinical data, safety data, protocol, know-how, computer program, software, software documentation, hardware
design, technology, product, processes, methods, techniques, formulas, compounds, projects, developments, research, development, marketing or business plan, forecast, unpublished financial statement, budget, license, price, cost, collaborator,
customer, supplier or personnel information or employee list that is communicated to, learned of, developed or otherwise acquired by the Executive in the course of performing his duties as a employee of the Company. 

(c) The Executive’s obligations under this Section 6.1 shall not apply to any information that (i) is or becomes known to
the general public under circumstances involving no breach by the Executive of the terms of this Section 6.1 or by others of the terms of 

  
 - 5 -

 
a similar agreement or obligation, (ii) is generally disclosed to third parties by the Company without restriction on such third parties, or (iii) is approved for release by written
authorization of the CEO. 
 (d) The Executive agrees that all files, documents, letters, memoranda, reports, records, data
sketches, drawings, models, laboratory notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible material containing Proprietary Information, whether created by the Executive or
others, which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by the Executive only in the performance of his duties for the Company and shall not be copied or removed from the Company
premises except in the pursuit of the business of the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the Executive shall be delivered to the Company, upon the earlier of
(i) a request by the Company or (ii) the termination of this Agreement. After such delivery, the Executive shall not retain any such materials or copies thereof or any such tangible property. 

(e) The Executive agrees that his obligation not to disclose or to use information and materials of the types set forth in paragraphs
(b) and (d) above, and his obligation to return materials and tangible property set forth in paragraph (d) above extends to such types of information, materials and tangible property of customers of the Company or suppliers to the
Company or other third parties who may have disclosed or entrusted the same to the Company or to the Executive. 
 (f) The
Executive acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the
course of work under such agreements or regarding the confidential nature of such work. The Executive agrees to be bound by all such obligations and restrictions that are known to him and to take all action necessary to discharge the obligations of
the Company under such agreements. 
 6.2 Inventions. 

(a) All inventions, creations, discoveries, computer programs, data, developments, technology, designs, innovations and improvements
(whether or not patentable and whether or not copyrightable) which are made, conceived, reduced to practice, created, written, designed or developed by the Executive, solely or jointly with others or under his direction and whether during normal
business hours or otherwise, (i) during the term of the Employment Agreement or during the Employment Period if made, conceived, reduced to practice, created, written, designed or developed in the course of Executive’s performance of
duties pursuant to this Agreement or (ii) during the term of the Employment Agreement or during or after the Employment Period if resulting or directly derived from Proprietary Information (collectively under clauses (i) and (ii),
“Inventions”), shall be the sole property of the Company. The Executive hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property
rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the 

  
 - 6 -

 
same before any government agency, court or authority. However, this paragraph shall not apply to Inventions which do not relate to the business or research and development conducted or
planned to be conducted by the Company at the time such Invention is created, made, conceived or reduced to practice and which are made and conceived by the Executive not during normal working hours, not on the Company’s premises and not using
the Company’s tools, devices, equipment or Proprietary Information. 
 (b) Upon the request of the Company and at the
Company’s expense, the Executive shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for,
obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention. The Executive also hereby waives all claims to moral rights in any Inventions. 

(c) The Executive shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in the
form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company
at all times. 
 7. Other Agreements. The Executive hereby represents that, except as the Executive has disclosed in
writing to the Company concurrently with the execution of the Employment Agreement, the Executive is not bound by the terms of any agreement with any third party to refrain from using or disclosing any trade secret or confidential or proprietary
information in the course of his employment with the Company, to refrain from competing, directly or indirectly, with the business of such third party or to refrain from soliciting employees, customers or suppliers of such third party. The Executive
further represents that his performance of all the terms of the Employment Agreement and this Agreement and the performance of his duties as an employee of the Company do not and will not breach any agreement with any third party to which the
Executive is a party (including, without limitation, any nondisclosure or non-competition agreement), and that the Executive will not disclose to the Company or induce the Company to use any confidential or proprietary information or material
belonging to any current or previous employer or others. 
 8. Non-Exclusivity. Subject to the terms of this Agreement,
the Executive retains the right to be employed by other companies and to contract with other companies or entities for his consulting services without restriction. 
 9. Remedies. The Executive acknowledges that any breach of the provisions of Section 6 of this Agreement shall result in serious and irreparable injury to the Company for which the Company
cannot be adequately compensated by monetary damages alone. The Executive agrees, therefore, that, in addition to any other remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Executive and
to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages or posting a bond. 

  
 - 7 -

 10. Notices. All notices required or permitted under this Agreement shall be in
writing and shall be deemed effective upon personal delivery or three days after deposit in the United States Post Office, by registered or certified mail (return receipt requested), postage prepaid, addressed to the other party at the address shown
above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10. 
 11. Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns
shall include the plural, and vice versa. 
 12. Entire Agreement. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements, including without limitation, the Employment Agreement, and any other understandings, whether written or oral, relating to the subject matter of this Agreement. 

13. Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the
Executive. 
 14. Non-Assignability of Contract. This Agreement is personal to the Executive and the Executive shall not
have the right to assign any of his rights or delegate any of his duties without the express written consent of the Company. Any non-consented-to assignment or delegation, whether express or implied or by operation of law, shall be void and shall
constitute a breach and a default by the Executive. 
 15. Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 

16. Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective
successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Executive are personal and shall not be assigned by
him. 
 17. Interpretation. If any restriction set forth in Section 6 is found by any court of competent
jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities
or geographic area as to which it may be enforceable. 
 18. Survival. Section 3.5 and Sections 4 through 20 shall
survive the expiration or termination of this Agreement. 
 19. Section 409A. 

19.1 The intent of the parties is that the payments and benefits under this Agreement comply with or be exempt from Section 409A of
the Internal Revenue Code of 1986, 

  
 - 8 -

 
as amended, and the regulations and guidance promulgated thereunder (collectively, “Section 409A”). Accordingly, to the maximum extent permitted, this Agreement shall be interpreted to
be in compliance therewith. 
 19.2 Notwithstanding anything in this Agreement to the contrary, any compensation or benefits
payable under this Agreement that are designated under this Agreement as payable upon the termination of this Agreement shall be payable only upon the Executive’s “separation from service” with the Company within the meaning of
Section 409A (a “Separation from Service”). 
 19.3 Notwithstanding anything in this Agreement to the contrary,
if the Executive is deemed by the Company at the time of the Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A, to the extent delayed commencement of any portion of the compensation or
benefits to which the Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of the Executive’s compensation or benefits shall not be provided to the Executive
prior to the earlier of (i) the expiration of the six-month period measured from the date of the Executive’s Separation from Service with the Company or (ii) the date of the Executive’s death. Upon the first business day
following the expiration of the applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to the Executive (or the Executive’s estate or beneficiaries), and any remaining payments
due to the Executive under this Agreement shall be paid as otherwise provided herein. 
 19.4 The Executive’s right to
receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted
under Section 409A. Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest pursuant to Section 409A.

 19.5 All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the
requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the
Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible for reimbursement in any other
calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or
liquidation or exchange for any other benefit. 

  
 - 9 -

 20. Miscellaneous. 

20.1 No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other
right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion. 

20.2 The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope
or substance of any section of this Agreement. 
 20.3 In the event that any provision of this Agreement shall be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 
 [Remainder of Page Intentionally Left Blank] 

  
 - 10 -

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year
set forth above. 
  

			
	BIND THERAPEUTICS, INC.
		
	By:	 	 /s/ Scott Minick

		 	Scott Minick, Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Daniel S. Lynch

	Daniel S. Lynch

 Signature Page to Employment Agreement 

 Exhibit A 
 NON-STATUTORY STOCK OPTION 
 Granted by 

BIND Therapeutics, Inc. (the “Company”) 
 Under the 2006 Stock Incentive Plan 
 This Option is and shall be subject in every
respect to the provisions of the Company’s 2006 Stock Incentive Plan, as amended from time to time (the “Plan”), which is incorporated herein by reference and made a part hereof. Capitalized terms used but not defined in this
agreement shall have the meanings given to them in the Plan. The holder of this Option (the “Holder”) hereby accepts this Option subject to all the terms and provisions of the Plan and agrees that (a) in the event of any conflict
between the terms hereof and those of the Plan, the latter shall prevail, and (b) all decisions under and interpretations of the Plan by the Board or the Committee shall be final, binding and conclusive upon the Holder and his or her heirs and
legal representatives. 
  

	1.	Name of Holder: Daniel S. Lynch 

  

	2.	Date of Grant:     June 28, 2013 

  

	3.	Maximum number of shares for 
which this Option is exercisable: 355,731 

 

	4.	Exercise (purchase) price per share: $3.57 

  

	5.	Payment method:  

 a
personal, certified or bank check or postal money order payable to the order of the Company for an amount equal to the exercise price of the shares being purchased; or 
 with the consent of the Company, any of the other methods set forth in the Plan. 
  

	6.	Expiration Date of the Option: June 27, 2023 

  

	7.	 Vesting Schedule: Subject to the Executive’s continued employment with or service to the Company on the applicable vesting date, the Option
shall vest and become exercisable as to 100% of the underlying shares on the first to occur, which must occur on or prior to December 31, 2013, of: (i) the closing of an initial public offering by the Company of the Company’s common
stock, (ii) the closing of one or more Funding Transactions (as defined below) that, in the reasonable, good faith judgment of the Board, cumulatively provide the Company with sufficient cash (together with the Company’s existing cash
resources on the date upon which such determination is made (the “Determination Date”)) to enable the Company to conduct its operations for at least two 

	 	
(2) years without the need for additional cash financing of the Company after the Determination Date by venture or private equity investors, and (iii) a Sale of the Company (collectively,
the “Performance Conditions”). The Holder shall not have the right to exercise this Option until the date the Option has become vested and exercisable. Unless otherwise determined by the Board, any portion of the Option that has not become
vested and exercisable on or prior to the date of termination of the Holder’s employment with or service to the Company (which, for the avoidance of doubt, shall include the Holder ceasing to provide services to the Company under the
circumstances described in clause (I) of the final sentence of Section 4.1 of the Amended and Restated Employment Agreement, dated June 28, 2013, between the Company and the Holder, as amended and/or restated from time to time (the
“Employment Agreement”)) shall be forfeited on the date of termination of the Holder’s employment with or service to the Company and shall not thereafter become vested or exercisable. 

For purposes of this Option, “Funding Transactions” shall mean licenses, collaborations, partnerships, government grants and
equity or other financing from strategic investors; and a “Sale” of the Company shall be any sale of all or substantially all of the outstanding shares of capital stock, assets or business of the Company, by merger, consolidation, sale of
assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Company’s voting securities immediately prior to such transaction beneficially own,
directly or indirectly, more than 50% (determined on an as-converted basis) immediately following the transaction of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or acquiring
corporation in such transaction). 
  

	8.	Termination of Employment/Service. This Option shall terminate on, and may not be exercised following, the earliest to occur of: 

 

	 	(i)	the Expiration Date of the Option set forth above; 

  

	 	(ii)	90 days after termination of the Holder’s employment with or services to the Company for any reason, including for the avoidance of doubt, the Holder ceasing to
provide services to the Company under the circumstances described in clause (I) of the final sentence of Section 4.1 of the Employment Agreement; and 

 

	 	(iii)	the Board’s determination after December 31, 2013 that none of the Performance Conditions has been satisfied and the Option has terminated.

  

	9.	Company’s Right of First Refusal. Prior to the effective date of a registration statement covering shares of the Company’s Common Stock, any shares of
stock issued pursuant to exercise of this Option shall be subject to the Company’s right of first refusal as set forth at Appendix A. 

  

	10.	 Lock-Up Agreement. The Holder agrees for a period of up to 180 days from the effective date of any registration of securities of the Company
under the Securities Act of 

	 	
1933, as amended (the “Securities Act”), upon request of the Company or underwriters managing any underwritten offering of the Company’s securities, not to sell, make any short
sale of, loan, grant any option for the purchase of, or otherwise dispose of any shares issued pursuant to the exercise of this Option, without the prior written consent of the Company and such underwriters. 

 

	11.	Tax Withholding. The Company’s obligation to deliver shares shall be subject to the Holder’s satisfaction of any federal, state and local income and
employment tax withholding requirements. 

  

	12.	Notice. Any notice to be given to the Company hereunder shall be deemed sufficient if addressed to the Company and delivered to the office of the Company, BIND
Therapeutics, Inc., 325 Vassar Street, Cambridge, Massachusetts 02139, attention of the president, or such other address as the Company may hereafter designate. Any notice to be given to the Holder hereunder shall be deemed sufficient if addressed
to and delivered in person to the Holder at his or her address furnished to the Company or when deposited in the mail, postage prepaid, addressed to the Holder at such address. 

IN WITNESS WHEREOF, the parties have executed this Option, or caused this Option to be executed, as of the Date of Grant. 

BIND Therapeutics, Inc. 

By:
                                     

        Andrew Hirsch, CFO 

The undersigned Holder hereby acknowledges receipt of a copy of the Plan and this Option (including Appendix A hereto), and agrees to the terms of this
Option and the Plan. 
  

                         
                         

 
 Holder: Daniel S. Lynch 

 APPENDIX A 
 Right of First Refusal 
 1.     General. Prior
to the effective date of a registration statement under the Securities Act of 1933, as amended (the “Act”), covering any shares of the Company’s Common Stock and until such time as the Company shall have effected a public offering of
its Common Stock registered under the Act, in the event that, at any time when the Holder (which term for purposes of this section shall mean the Holder and his or her executors, administrators and any other person to whom this Option may be
transferred by will or the laws of descent and distribution) is permitted to do so, the Holder desires to sell, assign or otherwise transfer any of the shares issued upon the exercise of this Option, the Holder shall first offer such shares to the
Company by giving written notice of the Holder’s desire so to sell, assign or transfer such shares. 

2.     Notice of Intended Transfer. The notice shall state the number of shares offered, the name of the
person or persons to whom it is proposed to sell, assign or transfer such shares and the price at which such shares are intended to be sold, assigned or transferred. Such notice shall constitute an offer to the Company for the Company to purchase
the number of shares set forth in the notice at a price per share equal to the price stated therein. 

3.     Company to Accept or Decline Within 30 Days. The Company may accept the offer as to all, but not less
than all, such shares by notifying the Holder in writing within 30 days after receipt of such notice of its acceptance of the offer. If the offer is accepted, the Company shall have 60 days within which to purchase the offered shares at a price per
share as aforesaid. If within the applicable time periods the Holder does not receive notice of the Company’s intention to purchase the offered shares, or if payment in full of the purchase price is not made by the Company, the offer shall be
deemed to have been rejected and the Holder may transfer title to such shares within 90 days from the date of the Holder’s written notice to the Company of the Holder’s intention to sell, but such transfer shall be made only to the
proposed transferee and at the proposed price as stated in such notice and after compliance with any other provisions of this Option applicable to the transfer of such shares. 
 4.     Transferred Shares to Remain Subject to Right of First Refusal. Shares that are so transferred to such transferee shall remain subject to the rights of the Company set
forth in this Appendix A. As a condition to such transfer, such transferee shall execute and deliver all such documents as the Company may require to evidence the binding agreement of such transferee so to remain subject to the rights of the
Company. 
 5.     Remedies of Company. No sale, assignment, pledge or transfer of any of the shares
covered by this Option shall be effective or given effect on the books of the Company unless all of the applicable provisions of this Appendix A have been duly complied with, and the Company may inscribe on the face of any certificate representing
any of such shares a legend referring to the provisions of this Appendix A. If any transfer of shares is made or attempted in violation of the foregoing restrictions, or if shares are not offered to the Company as required hereby, the Company shall
have the right to purchase such shares from the owner thereof or his transferee at any time before or after the transfer, as herein provided. In addition to any other 

 
legal or equitable remedies which it may have, the Company may enforce its rights by actions for specific performance (to the extent permitted by law) and may refuse to recognize any transferee
as one of its stockholders for any purpose, including, without limitation, for purposes of dividend and voting rights, until all applicable provisions hereof have been complied with. 

6.     Shares Subject to Right of First Refusal. For purposes of the Right of First Refusal pursuant to this
Appendix A, the term “shares” shall mean any and all new, substituted or additional securities or other property issued to the Holder, by reason of his or her ownership of Common Stock pursuant to the exercise of this Option, in connection
with any stock dividend, liquidating dividend, stock split or other change in the character or amount of any of the outstanding securities of the Company, or any consolidation, merger or sale of all or substantially all of the assets of the Company.

 7.     Legends on Stock Certificates. Any certificate representing shares of stock subject to the
provisions of this Appendix A may have endorsed thereon one or more legends, substantially as follows: 
  

	 	(i)	“Any disposition of any interest in the securities represented by this certificate is subject to restrictions, and the securities represented by this certificate
are subject to certain options, contained in a certain agreement between the record holder hereof and the Company, a copy of which will be mailed to any holder of this certificate without charge upon receipt by the Company of a written request
therefor.” 

  

	 	(ii)	“The shares of stock represented by this certificate have not been registered under the Securities Act of 1933 or under the securities laws of any state and may
not be pledged, hypothecated, sold or otherwise transferred except upon such registration or upon receipt by the Company of an opinion of counsel satisfactory to the Company, in form and substance satisfactory to the Company, that such registration
is not required.” 

 8.     Right of First Refusal to Lapse Upon Registration. The
restrictions imposed by this Appendix A shall terminate in all respects upon the effective date of a registration statement under the Act covering any of the Company’s Common Stock. 

 Exhibit B 

SEPARATION AGREEMENT AND RELEASE 
 This Separation Agreement and Release (“Agreement”) is made by and between Daniel S. Lynch (“Executive”) and BIND Therapeutics, Inc. (the “Company”)
(collectively, referred to as the “Parties” or individually referred to as a “Party”). 

WHEREAS, the Parties have previously entered into that certain Amended and Restated Employment Agreement, dated as of June 28, 2013
(the “Employment Agreement”); and 
 WHEREAS, in connection with the termination of the Employment Agreement,
the Parties wish to resolve any and all disputes, claims, complaints, grievances, charges, actions, petitions, and demands that the Executive may have against the Company and any of the Releasees (as defined below) arising out of or related to
Executive’s employment with or separation from the Company or its subsidiaries or affiliates or the termination of the Agreement (the “Employment Relationship”) but, for the avoidance of doubt, nothing herein will be deemed to
release any rights or remedies in connection with amounts owed to, or vested benefits for, the Executive (or his immediate family members) under Sections 3.1, 3.3 and 3.4 of the Employment Agreement through the effective date of termination thereof,
Executive’s ownership of vested equity securities of the Company, Executive’s right to indemnification by the Company or any of its affiliates pursuant to contract or applicable law or Directors’ and Officers’ insurance, or
Executive’s rights to payments under this Agreement (collectively, the “Retained Claims”). 
 NOW,
THEREFORE, in consideration of the payment to the Executive of the compensation and benefits described in Section 3.5(a) of the Employment Agreement (the “Severance Payments”), which, pursuant to the Employment Agreement, are
conditioned on the Executive’s execution and non-revocation of this Agreement, and in consideration of the mutual promises made herein, the Company and Executive hereby agree as follows: 

1. Severance Payments. The Company agrees to provide Executive with the Severance Payments, payable at the times set forth in, and
subject to the terms and conditions of, the Employment Agreement. 
 2. Release of Claims. Executive agrees that, other
than with respect to the Retained Claims, the foregoing consideration represents settlement in full of all outstanding obligations owed to Executive by the Company, any of its direct or indirect subsidiaries and affiliates, and any of its or their
current and former officers, directors, equity holders, managers, employees, agents, investors, attorneys, shareholders, administrators, affiliates, benefit plans, plan administrators, insurers, trustees, divisions, and subsidiaries and predecessor
and successor corporations and assigns (collectively, the “Releasees”) arising out of or related to the Employment Relationship. Executive, on his own behalf and on behalf of Executive’s heirs, family members, executors,
agents, successors and assigns, other than with respect to the Retained Claims, hereby and forever releases the Releasees from, and agrees not to sue concerning, or in any manner to institute, prosecute, or pursue, any claim, complaint, charge,
duty, obligation, or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected, that Executive may possess against any of the Releasees 

 
arising from any omissions, acts, facts, or damages that have occurred up until and including the Effective Date of this Agreement (as defined in Section 7 below) and arising out of
or related to the Employment Relationship, including, without limitation, to the extent arising out of or related to the Employment Relationship: 
 (a) any and all claims relating to, or arising from, Executive’s right to purchase, or actual purchase of any shares of stock or other equity interests of the Company or any of its affiliates,
including, without limitation, any claims for fraud, misrepresentation, breach of fiduciary duty, breach of duty under applicable state corporate law, and securities fraud under any state or federal law; 

(b) any and all claims for wrongful dismissal or discharge of employment; termination in violation of public policy;
discrimination; harassment; retaliation; breach of contract, both express and implied; breach of covenant of good faith and fair dealing, both express and implied; promissory estoppel; negligent or intentional infliction of emotional distress;
fraud; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective economic advantage; unfair business practices; defamation; libel; slander; negligence; personal injury; assault; battery; invasion
of privacy; false imprisonment; conversion; and disability benefits; 
 (c) any and all claims for violation of
any federal, state, or municipal statute, including, but not limited to, Title VII of the Civil Rights Act of 1964; the Civil Rights Act of 1991; the Rehabilitation Act of 1973; the Americans with Disabilities Act of 1990; the Equal Pay Act; the
Fair Credit Reporting Act; the Age Discrimination in Employment Act of 1967; the Older Workers Benefit Protection Act; the Employee Retirement Income Security Act of 1974; the Worker Adjustment and Retraining Notification Act; the Family and Medical
Leave Act; the Sarbanes-Oxley Act of 2002; the Massachusetts Fair Employment Practices Act; the Massachusetts Civil Rights Act; the Massachusetts Equal Rights Act; the Massachusetts Labor and Industries Act; the Massachusetts Privacy Act; and the
Massachusetts Maternity Leave Act, all as amended; 
 (d) any and all claims for violation of the federal or any
state constitution; 
 (e) any and all claims arising out of any other laws and regulations relating to
employment or employment discrimination; 
 (f) any claim for any loss, cost, damage, or expense arising out of
any dispute over the non-withholding or other tax treatment of any of the proceeds received by Executive as a result of this Agreement; and 
 (g) any and all claims for compensatory damages, punitive damages, injunctive relief, attorneys’ fees and costs. 
 Executive agrees that the release set forth in this section shall be and remain in effect in all respects as a complete general release as to the matters released. This release does not release claims
that cannot be released as a matter of law, including, but not limited to, Executive’s right to file a charge with or participate in a charge by the Equal Employment Opportunity Commission, or any other local, state, or federal administrative
body or government agency that 

 
is authorized to enforce or administer laws related to employment, against the Company (with the understanding that Executive’s release of claims herein bars Executive from recovering
monetary relief from the Company or any Releasee), claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law, claims to continued participation in certain of the Company’s
group benefit plans pursuant to the terms and conditions of COBRA, claims to any benefit entitlements vested as the date of separation of Executive’s employment, pursuant to written terms of any employee benefit plan of the Company or its
affiliates and Executive’s rights under applicable law, and any Retained Claims. 
 3. Acknowledgment of Waiver of
Claims under ADEA. Executive understands and acknowledges that Executive is waiving and releasing any rights Executive may have under the Age Discrimination in Employment Act of 1967 (“ADEA”), and that this waiver and release is
knowing and voluntary. Executive understands and agrees that this waiver and release does not apply to any rights or claims that may arise under the ADEA after the Effective Date of this Agreement. Executive understands and acknowledges that the
consideration given for this waiver and release is in addition to anything of value to which Executive was already entitled. Executive further understands and acknowledges that Executive has been advised by this writing that: (a) Executive
should consult with an attorney prior to executing this Agreement; (b) Executive has 21 days within which to consider this Agreement; (c) Executive has 7 days following Executive’s execution of this Agreement to revoke this Agreement
pursuant to written notice to the Secretary of the Company; (d) this Agreement shall not be effective until after the revocation period has expired; and (e) nothing in this Agreement prevents or precludes Executive from challenging or
seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties, or costs for doing so, unless specifically authorized by federal law. In the event Executive signs this
Agreement and returns it to the Company in less than the 21 day period identified above, Executive hereby acknowledges that Executive has freely and voluntarily chosen to waive the time period allotted for considering this Agreement. 

4. Severability. In the event that any provision or any portion of any provision hereof or any surviving agreement made a part
hereof becomes or is declared by a court of competent jurisdiction or arbitrator to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision or portion of provision. 

5. No Oral Modification. This Agreement may only be amended in a writing signed by Executive and a duly authorized officer of the
Company. 
 6. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts without giving effect to any choice or conflict of law provision or rule that would cause the application of laws of any other jurisdiction. 
 7. Effective Date. If Executive has attained or is over the age of 40 as of the date of Executive’s termination of employment, then Executive has seven days after Executive signs this
Agreement to revoke it and this Agreement will become effective on the eighth day after Executive signed this Agreement, so long as it has been signed by the Parties and has not been revoked by either Party before that date (the “Effective
Date”). If Executive has not attained the age of 40 as of the date of Executive’s termination of employment, then the “Effective Date” shall be the date on which Executive signs this Agreement. 

 8. Voluntary Execution of Agreement. Executive understands and agrees that Executive
executed this Agreement voluntarily, without any duress or undue influence on the part or behalf of the Company or any third party, with the full intent of releasing all of Executive’s claims as set forth above against the Company and any of
the other Releasees arising out of or related to the Employment Relationship. Executive acknowledges that: (a) Executive has read this Agreement; (b) Executive has not relied upon any representations or statements made by the Company that
are not specifically set forth in this Agreement; (c) Executive has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of Executive’s own choice or has elected not to retain legal counsel;
(d) Executive understands the terms and consequences of this Agreement and of the releases it contains; and (e) Executive is fully aware of the legal and binding effect of this Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the respective dates set
forth below. 
  

									
		 		 		 	EXECUTIVE
				
	Dated:	 	  
	 		 	  

		 		 		 	Daniel S. Lynch
				
		 		 		 	COMPANY
				
		 		 		 	BIND THERAPEUTICS, INC.
					
	Dated:	 	  
	 		 	By:	 	  

		 		 		 	Name:	 	  

		 		 		 	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00220-of-00352.parquet"}]]